Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term cancer risk in acromegaly: a population-based cohort study with 44 years of follow-up.

European journal of endocrinology·2026
Same author

Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study).

BMJ open·2026
Same author

Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome.

Nature genetics·2026
Same author

Prolactin measurements in a real-life setting: a population-based cohort study.

Pituitary·2026
Same author

Growth hormone causes reversible fibrosis in muscle and fat: a study in patients with acromegaly.

European journal of endocrinology·2026
Same author

Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol.

BMJ open·2026

Related Experiment Video

Updated: Jul 16, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

[Acromegaly: new principles for treatment].

Jens Otto Lunde Jørgensen1, Ulla Friis Feldt-Rasmussen, Marianne Andersen

  • 1Arhus Universitetshospital, Arhus Sygehus, Medicinsk Afdeling M, Arhus C. jolj@dadlnet.dk

Ugeskrift for Laeger
|March 16, 2007
PubMed
Summary

Acromegaly treatment aims to normalize mortality rates. While surgery and somatostatin analogues are common, pegvisomant offers complete growth hormone (GH) suppression and improves glucose tolerance.

Related Experiment Videos

Last Updated: Jul 16, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Acromegaly is a rare endocrine disorder caused by excess growth hormone (GH), often from a pituitary tumor.
  • Effective management is crucial to reduce the elevated mortality associated with acromegaly.
  • Current treatments include surgery and somatostatin analogues, with varying success rates.

Purpose of the Study:

  • To review the efficacy and limitations of current acromegaly treatments.
  • To evaluate the potential of pegvisomant, a novel GH receptor antagonist, in managing acromegaly.

Main Methods:

  • Literature review of surgical outcomes for pituitary tumors.
  • Analysis of clinical trial data for somatostatin analogues.
  • Assessment of studies on pegvisomant's efficacy and safety profile.

Main Results:

  • Surgery is effective in 50-60% of acromegaly patients.
  • Somatostatin analogues normalize GH in 60% and shrink tumors in 30%.
  • Pegvisomant demonstrates complete GH activity suppression in most patients and improves glucose tolerance, but does not suppress tumor activity.

Conclusions:

  • Pegvisomant represents a promising therapeutic option for acromegaly, particularly for its ability to normalize GH activity.
  • Further research is needed to address pegvisomant's limitations, including lack of tumor suppression and high cost.
  • Optimizing acromegaly management requires a comprehensive approach considering individual patient needs and treatment efficacy.